KR20220128545A - A pharmaceutical composition for preventing or treating liver fibrosis containing Lactobacillus delbrueckii subsp. lactis CKDB001 - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis, a health functional food composition for preventing or alleviating liver fibrosis, and a health food composition for preventing or alleviating liver fibrosis, all of which include a Lactobacillus delbrueckii subsp. lactis CKDB001 strain. When the Lactobacillus delbrueckii subsp. lactis CKDB001 strain is administered to liver fibrosis-induced mice, it is possible to decrease fibrosis gene expression in liver tissues, and have an effect of pathologically protecting and inhibiting liver fibrosis, thereby being able to be used for preventing and treating liver fibrosis.

Description

Lactobacillus delbrooki subsp. A pharmaceutical composition for preventing or treating liver fibrosis containing Lactobacillus delbrueckii subsp. lactis CKDB001}

The present invention is Lactobacillus delbrooki subsp. It relates to a pharmaceutical composition for preventing or treating liver fibrosis, a health functional food composition for preventing or improving liver fibrosis, and a health food composition for preventing or improving liver fibrosis, comprising the lactis CKDB001 strain.

Because about 60% of the immune cells of the human body are impaired, the body must be healthy when the intestine is healthy. Irregular lifestyle and stress of modern people cause an imbalance of intestinal bacteria, which affects gut health. At this time, lactic acid bacteria help to increase the beneficial bacteria in the intestine and reduce the harmful bacteria, thereby regulating the intestinal microflora. The gut microbiome plays an important role in health and disease. By increasing the ratio of beneficial bacteria through the regulation of the intestinal microflora, it can be used to improve various diseases such as immunomodulatory activity effect, reduction of fasting blood sugar, and prevention of pathogenic bacteria adhesion and invasion [Hallajzadeh J, Eslami RD, Tanomand A. Effect of Lactobacillus delbrueckii Subsp. lactis PTCC1057 on Serum Glucose, Fetuin-A, and Sestrin 3 Levels in Streptozotocin-Induced Diabetic Mice. Probiotics Antimicrob Proteins 2020, Yu Q, Zhu L, Wang Z, Li P, Yang Q. Lactobacillus delbrueckii ssp. lactis R4 prevents Salmonella typhimurium SL1344-induced damage to tight junctions and adherens junctions. J Microbiol 2012; 50:613-7].

Lactobacilli can live by forming colonies in the intestine through various mechanisms in the stomach and intestines. Because the beneficial effect of lactic acid bacteria by the intestinal-liver axis can be extended to improvement of liver function in cirrhosis, nonalcoholic fatty liver disease and alcoholic liver disease, it is possible to improve the intestinal environment and liver disease through lactic acid bacteria administration [Sharma V, Garg S, Aggarwal S. Probiotics and liver disease. Perm J 2013; 17:62-7].

Liver fibrosis is a condition in which liver fibers are increased, and it is caused by excessive accumulation of extracellular matrix proteins including collagen, which occurs mostly in chronic liver disease. Progressive liver fibrosis causes cirrhosis, liver failure and portal hypertension and may require liver transplantation [Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-18].

Hepatic cholestatic disease represents an associated cause of chronic liver disease associated with severe mortality. Understanding and addressing therapeutic strategies for this is essential for developing in vivo models that recapitulate pathological features. The supply of 3,5-diethoxycarbonyl-1,4-dihydrocollidine, named DDC, is a biomodel of cholestatic disease, reproducing the major pathological features of human cholestatic disease, such as fibrosis and inflammatory infiltration [ Pose E, Sancho-Bru P, Coll M. 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine Diet: A Rodent Model in Cholestasis Research. Methods Mol Biol 2019; 1981:249-57].

The typical toxicity of carbon tetrachloride, named CCl ₄ , is a representative substance that causes cirrhosis and liver fibrosis. This induced hepatic fibrosis can progress to hepatocarcinoma as a result of chronic liver lesions. Carbon tetrachloride can be induced by inhalation, oral or intragastric administration, subcutaneous injection and intraperitoneal injection, and can be induced faster by mixing it with drinking water and administering it [Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, et al. al. Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. J Toxicol Sci 2016; 41:561-72].

Antibiotics work to eliminate harmful bacteria from our body. However, overuse and abuse of antibiotics causes side effects such as allergic reactions, rashes, and diarrhea, and resistance that decreases the efficacy of antibiotics when continuously exposed to low concentrations of antibiotics. If antibiotics are used in animal breeding to prevent harmful bacterial infections, antibiotic residues such as milk, eggs and meat can remain. These residues can cause various immunopathological side effects of antibiotic-resistant bacteria [Bacanli M, Basaran N. Importance of antibiotic residues in animal food. Food Chem Toxicol 2019; 125:462-6].

Probiotics can be used as a substitute for antibiotics as live lactic acid bacteria for feeding livestock to improve the productivity of livestock by enhancing resistance to harmful bacteria, and can also play a role in controlling harmful bacteria in the human body. However, in order to exploit the beneficial properties of these probiotics, it is important to determine the effects of microorganisms in the digestive tract of humans and animals. As such, it can be expected to develop therapeutic agents for modern diseases by using probiotics that restore or improve the intestinal microflora.

The present invention is Lactobacillus delbrooki subsp. The purpose of this study is to propose a candidate probiotic as a treatment for hepatic fibrosis as the lactis CKDB001 strain improves liver fibrosis and has an immune-enhancing effect by regulating the intestinal microflora.

In addition, the problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.

According to one embodiment of the present invention in order to achieve the above object, accession number KCTC 14149BP Lactobacillus delbrooki subsp. There is provided a pharmaceutical composition for preventing or treating liver fibrosis comprising the lactis CKDB001 strain as an active ingredient.

According to an embodiment of the present invention, the Lactobacillus delbrooki subsp. The lactis CKDB001 strain may be isolated from fermented milk.

According to an embodiment of the present invention, the Lactobacillus delbrooki subsp. The lactis CKDB001 strain may be included in the form of a powdered probiotic.

According to another embodiment of the present invention, accession number KCTC 14149BP Lactobacillus delbrooki subsp. There is provided a health functional food composition for preventing or improving liver fibrosis comprising the lactis CKDB001 strain.

According to an embodiment of the present invention, the health functional food may be food in the form of tablets, capsules, pills, or liquids.

On the other hand, according to another embodiment of the present invention, accession number KCTC 14149BP Lactobacillus delbrooki subsp. There is provided a health food composition for preventing or improving liver fibrosis comprising the lactis CKDB001 strain.

According to an embodiment of the present invention, the health food is a drink, meat, sausage, bread, candy, snack, noodles, ice cream, dairy product, soup, ionic beverage, beverage, alcoholic beverage, gum, tea and vitamin complex consisting of It may be at least one selected from the group.

Lactobacillus delbrooki subsp according to the present invention. When lactis CKDB001 ( Lactobacillus delbrueckii subsp . lactis CKDB001 ) strain is administered to hepatic fibrosis-induced mice, it reduces the expression of fibrosis genes in liver tissue and has the effect of protecting and inhibiting pathologically from hepatic fibrosis. can be used for treatment.

1 is a schematic diagram of a mouse model of liver fibrosis induced by DDC dietary intake.
Figure 2 is Lactobacillus delbrooki subsp in the DDC model. It is a comparison diagram of the protective effect on body weight and liver weight of the lactis CKDB001 strain.
3 is a Lactobacillus delbrooki subsp in the DDC model. It is a measure of inhibition of fibrosis gene expression of lactis CKDB001 strain.
Figure 4 is Lactobacillus delbrooki subsp in the DDC diet model. It is a pathological comparison diagram of inhibition of fibrosis progression of lactis CKDB001 strain.
5 is a schematic diagram of a mouse model of liver fibrosis induced by CCl ₄ injection.
Figure 6 is CCl ₄ Lactobacillus delbrooki subsp in the model. It is a comparison diagram of the protective effect on body weight and liver weight of the lactis CKDB001 strain.
7 is a Lactobacillus delbrooki subsp in the CCl ₄ model. It is a measure of the inhibition of fibrosis gene expression of the lactis CKDB001 strain.
Figure 8 is Lactobacillus delbrooki subsp in the CCl ₄ model. It is a pathological comparison diagram of inhibition of fibrosis progression of the lactis CKDB001 strain.

Hereinafter, the present invention will be described in detail. Prior to this, the terms or words used in the present specification and claims should not be construed as being limited to their ordinary or dictionary meanings, and the inventor should properly understand the concept of the term in order to best describe his invention. It should be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle that it can be defined in Therefore, the configuration described in the embodiment described in this specification is only the most preferred embodiment of the present invention and does not represent all of the technical idea of the present invention, so various equivalents and It should be understood that there may be variations.

According to an embodiment of the present invention, Lactobacillus delbrooki subsp. There is provided a pharmaceutical composition for preventing or treating liver fibrosis comprising the lactis CKDB001 strain as an active ingredient. In the present invention, Lactobacillus delbrooki subsp. The lactis CKDB001 strain was deposited with the "Korean Collection for Type Culture (KCTC)" with accession number "KCTC 14149BP". Hereinafter, the Lactobacillus delbrooki subsp. Lactis CKDB001 strain ( Lactobacillus delbrueckii subsp . lactis CKDB001 ) can be used in combination with L. lactis CKDB001.

On the other hand, according to an embodiment of the present invention, the Lactobacillus delbrooki subsp. The lactis CKDB001 strain may be isolated from fermented milk.

In addition, the Lactobacillus delbrooki subsp. The Lactis CKDB001 strain may be contained in the form of a probiotic powder, and more specifically, 1.10E+11 colony forming units (CFU) per 1 gram (g) of the Lactobacillus delbrooki subsp. A probiotic of lactis CKDB001 strain powder can be provided.

According to an embodiment of the present invention, Lactobacillus delbrooki subsp. There is provided a health functional food composition for preventing or improving liver fibrosis comprising the lactis CKDB001 strain.

In this case, the health functional food may be food in the form of tablets, capsules, pills, or liquids.

According to an embodiment of the present invention, Lactobacillus delbrooki subsp. There is provided a health food composition for preventing or improving liver fibrosis comprising the lactis CKDB001 strain.

Lactobacillus delbrooki subsp of the present invention. When the lactis CKDB001 strain is used as a health functional food and health food composition, there is no particular limitation on the type of food. Lactobacillus delbrooki subsp of the present invention. Examples of foods to which the lactis CKDB001 strain can be added include drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, and various There are soups, beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, and includes all health functional foods and health food compositions in the ordinary sense.

Lactobacillus delbrooki subsp according to the present invention. The health functional food and health food composition containing the lactis CKDB001 strain may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method. Lactobacillus delbrooki subsp. The mixing amount of the lactis CKDB001 strain may be appropriately determined depending on the purpose of its use (for prevention or improvement). In general, the amount of the composition in the health functional food and health food composition may be added in an amount of 0.1 to 90 parts by weight based on the total weight of the food. However, in the case of long-term ingestion for the purpose of maintaining health or for health control, the amount may be less than the above range.

Lactobacillus delbrooki subsp of the present invention. There is no particular limitation on other ingredients other than containing the lactis CKDB001 strain, and it may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 g of the health functional food and health food composition of the present invention.

In addition to the above, Lactobacillus delbrooki subsp. The health functional food and health food composition containing the lactis CKDB001 strain contains various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pect acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the health functional food and health food composition of the present invention may contain natural fruit juice, fruit juice, and fruit for the production of a vegetable drink.

Hereinafter, the present invention will be described in more detail by way of Examples. These examples are merely for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited to these examples.

Example 1. Lactobacillus delbrooki subsp. Isolation of Lactis CKDB001 strain

1. Characterization and Identification of Probiotic Microbial Candidates

The probiotic microorganism of the present invention was isolated from fermented crude oil and was provided by Chong Kun Dang Bio. Probiotics Lactobacilli are Gram-positive. Characteristics were confirmed according to the following criteria.

1) In vitro safety measurement

2) Stability during movement from the oral cavity through the stomach to the intestine

3) Antibiotic susceptibility

The results of measuring these characteristics are summarized in Table 1 below.

Lactobacillus delbrooki subsp. Phenotypic Characteristics of Lactis CKDB001 Strain go) Gastrointestinal environmental stability (survival rate) acid resistance biliary tolerance 95% 98% me) harmful enzyme activity Gelatinase Urease Hemolysis voice voice voice all) Antibiotic susceptibility (μg/ml) Ampicillin 0.19 Vancomycin 0.5 Gentamicin One Erythromycin 0.047 Clindamycin 0.094 Tetracycline 0.75 Streptomycin 4 Kanamycin 16 Chloramphenicol 4 la) HT-29 cells (enterocytes) adhesion capacity 152% (compared to control)

2. Identification of selected strains

go) Lactobacillus delbrooki subsp. Identification of Lactis CKDB001 strain

This strain was identified as Lactobacillus delbrueckii subsp. lactis was identified. Isolated Lactobacillus delbrooki subsp. The lactis CKDB001 strain was maintained as a biologically pure culture to make it a probiotic.

B) Identified Lactobacillus delbrooki subsp. Biochemical test against lactis CKDB001 strain

Lactobacillus delbrooki subsp. Lactis CKDB001 strain was identified by Gram staining and microscopic observation.

Example 2. Lactobacillus delbrooki subsp. Preparation of Lactis CKDB001 strain composition

Lactobacillus delbrooki subsp. Lactis CKDB001 strain was supplied by Chong Kun Dang Bio. Purified Lactobacillus delbrooki subsp. Lactis CKDB001 strain was delivered in the form of lyophilized fine powder.

1. Lyophilized Lactobacillus delbrooki subsp. Lactis CKDB001 strain prepared in fine powder form

2. Prepared with special coating treatment by Chong Kun Dang Bio to increase the survival rate weak to gastric acid

3. Lactobacillus delbrooki subsp. Lactis CKDB001 strain was suspended in distilled water at a concentration of 10 ⁹ CFU/g and supplied twice a week.

Example 3. Hepatic fibrosis induction mouse model induction and analysis method

For animal model evaluation, 5-week-old C57BL/6J male mice without specific pathogens were purchased from Dooyeol Biotech (Seoul, Korea). All mice were individually housed in dedicated cages at a temperature of 22±2° C. with a 12/12 h light/dark cycle. During the experiment, all mice had free access to water and food and were observed daily. The experiment included an adaptation period for all groups, and normal feed was provided for 1 week during this period. The laboratory animals received humanitarian treatment, and all procedures followed the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals, and were approved by the Animal Experiment and Use Committee (2019-4) of Hallym University College of Medicine.

1. 3,5-diethoxycarbonyl-1,4-dihydrocollidine model

In order to induce a liver fibrosis model through dietary intake, a 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (hereinafter abbreviated DDC) mixed feed was prepared by Dooyeol Biotech and allowed to be freely consumed for 3 weeks. Hepatic fibrosis model mice were classified into three groups ( FIG. 1 ): normal (n=6), disease-inducing diet (n=6), and Lactobacillus delbrooki subsp with disease-inducing diet. Lactis CKDB001 strain intake (n=6).

2. Carbon tetrachloride model

To induce a liver fibrosis model by intraperitoneal injection, corn oil (Sigma, USA) and carbon tetrachloride (hereinafter abbreviated CCl ₄ ) (Showa, Japan) were diluted 4:1 and intraperitoneally injected twice a week for 10 weeks to establish a liver fibrosis model did. Hepatic fibrosis model mice were classified into three groups ( FIG. 5 ): normal (n=6), disease-inducing injection (n=6), and Lactobacillus delbrooki subsp with disease-inducing injection. Lactis CKDB001 strain intake (n=6).

3. Treatment method

After 4 weeks and 11 weeks according to each animal model, animals were sacrificed by administration of an inhaled anesthetic (Airlane solution, USA). Body weight and liver weight were measured, and blood and liver tissues were isolated. A sample of whole blood (800 μL) was centrifuged (19,000 g, 5 min) to separate serum. Liver tissue was quickly isolated and stored at 80 °C.

4. Pathological analysis

The isolated liver tissue was fixed with 10% formalin and embedded in paraffin, and tissue sections were stained with hematoxylineosin (H&E), mason trichrome (MT), and Sirius Red (SR). Grading pathological analysis used for the analysis of liver cirrhosis (inflammation, fractional or bridging necrosis [grade 0: none, 1: portal inflammation or lobular inflammation without necrosis, 2: mild periportal inflammation and fragmentary necrosis or focal hepatocellular necrosis, 3: moderate portal vein inflammation and fragment necrosis or severe focal cell injury, 4: severe periportal inflammation and fragment necrosis or bridge necrosis]) and staging (grade 0: no fibrosis, 1: dilated fibrotic portal vein, 2: periportal fibrosis or portal vein to portal septum, no structural distortion, 3: fibrotic linkage with structural distortion, no apparent cirrhosis, 4: possible or confirmed cirrhosis]).

5. Analysis of liver tissue for fibrosis factor

Isolation of mRNA from tissues was performed using the Trizol reagent kit (Invitrogen, USA) according to the manufacturer's instructions. mRNA (2 μg) was synthesized into cDNA using a cDNA synthesis kit (Applied Biosystems, USA). Quantitative PCR (qPCR) was performed for cDNA using Luna Universal Master Mix (New England Biolab, USA) and each target-specific probe-primer.

6. Data Analysis

Continuous variables were analyzed as mean and standard deviation. One-way ANOVA, the Kruskal-Wallis test, and independent sample T-test were performed for body weight, fibrosis factor and histological analysis. Data were based on MSTUS55 from NOREVA (http://idrb.zju.edu.cn/noreva) for further statistical analysis. Hierarchical cluster analysis (HCA) was performed and analysis of variance (ANOVA) with post-test was performed using a multiple experiment viewer (MeV). A significance probability P value <0.05 is considered to indicate statistical significance. All statistical analyzes were performed using SPSS software (ver. 19, SPSS Inc., Chicago, IL, USA).

Example 4. Lactobacillus delbrooki subsp. Measurement of liver fibrosis inhibition ability in a mouse model of hepatic fibrosis induction of lactis CKDB001 strain

1. Inhibitory effect of hepatic fibrosis factor in hepatic fibrosis-induced mouse model

The most characteristic feature of liver fibrosis disease is the progression of fibrosis. There are various causes of fibrosis, such as overexpression of TGF-β and abnormal activity of hepatic stellate cells. Although the exact cause has not yet been elucidated, representative fibrosis factors (Timp1, Col1a, and TGF-β) in liver fibrosis can be usefully used in the evaluation of diseases. Therefore, the expression of each fibrosis factor in the liver fibrosis induction model was comparatively analyzed through qPCR. The greatly increased expression of Timp1, Col1a, and TGF-β due to the induction of hepatic fibrosis was found in Lactobacillus delbrooki subsp. It was confirmed that the lactis CKDB001 strain was significantly reduced by ingestion.

A) DDC model

Lactobacillus delbrooki subsp. Lactis CKDB001 strain was administered. While inducing liver fibrosis, Lactobacillus delbrooki subsp. When the lactis CKDB001 strain was administered, the expression of Col1a, Timp1 and TGF-β, which are representative fibrotic factors in cirrhosis, was significantly reduced. In the case of Col1a, Lactobacillus delbrooki subsp. When administered with lactis CKDB001 strain, 12±2.4 ( p <0.05), for Timp1, from 53.1±7.6 to 32.8±1.9 ( p <0.05), and for TGF-β, 8.1±1.7 to 5.1±0.7 ( p <0.05) was reduced to (see FIG. 3).

B) CCl ₄ model

Hepatic fibrosis induction injection was administered intraperitoneally for 10 weeks, and Lactobacillus delbrooki subsp. Lactis CKDB001 strain was administered. In the case of Col1a, Lactobacillus delbrooki subsp. Lactis CKDB001 strain administered 16.9±5.5 ( p <0.05), Timp1 5.2±1.4 to 2.2±1.2 ( p <0.05), and TGF-β 2.2±0.5 to 1.6±0.6 ( p <0.05) was reduced to (see FIG. 7).

3. Lactobacillus delbrooki subsp. The protective effect of liver cirrhosis in a mouse model of hepatic fibrosis induction of lactis CKDB001 strain

Pathological analysis was performed to more reliably confirm liver fibrosis of cirrhosis. Liver tissue was performed by staining with hematoxylineosin, mason trichrome, and Sirius Red. In the hepatic fibrosis induction model, fibrosis was increased, and the grading, staging, and Sirius red measurement areas were significantly increased compared to the normal control group. Lactobacillus delbrooki subsp. The protective effect was confirmed by reducing all of the increased grading, staging, and Sirius Red measurement area through ingestion of the Lactis CKDB001 strain.

A) DDC model

When the liver fibrosis model was induced, the Sirius red staining area was 43.1±5.5 and Lactobacillus delbrooki subsp. When the lactis CKDB001 strain was ingested, it decreased to 22.7±11.4 ( p <0.01).

B) CCl ₄ model

Lactobacillus delbrooki subsp. in grade 3 upon induction of hepatic fibrosis model. When the Lactis CKDB001 strain was ingested, it was 2.8±0.2, and in stage 3, Lactobacillus delbrooki subsp. When the lactis CKDB001 strain was ingested, it was reduced to 2.8±0.4. Sirius red staining area was 29.8±6 and Lactobacillus delbrooki subsp. When the lactis CKDB001 strain was ingested, it was reduced to 24±3.8.

As the specific parts of the present invention have been described in detail above, for those of ordinary skill in the art, it is clear that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. will be. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.

Claims (9)

Accession number KCTC 14149BP Lactobacillus delbrooki subsp. A pharmaceutical composition for preventing or treating liver fibrosis comprising the lactis CKDB001 strain as an active ingredient. According to claim 1,
The Lactobacillus delbrooki subsp. Lactis CKDB001 strain is a pharmaceutical composition for preventing or treating liver fibrosis, which is isolated from fermented raw milk. According to claim 1,
The Lactobacillus delbrooki subsp. Lactis CKDB001 strain is a pharmaceutical composition for preventing or treating liver fibrosis, which is contained in the form of a probiotic powder. Accession number KCTC 14149BP Lactobacillus delbrooki subsp. A health functional food composition for preventing or improving liver fibrosis, comprising the lactis CKDB001 strain. 5. The method of claim 4,
The health functional food is a health functional food composition for preventing or improving liver fibrosis, which is a food in the form of a tablet, capsule, pill or liquid. 5. The method of claim 4,
The Lactobacillus delbrooki subsp. Lactis CKDB001 strain is a health functional food composition for preventing or improving liver fibrosis, which is isolated from fermented raw milk. 5. The method of claim 4,
The Lactobacillus delbrooki subsp. Lactis CKDB001 strain is a health functional food composition for preventing or improving liver fibrosis, which is contained in the form of a probiotic powder. Accession number KCTC 14149BP Lactobacillus delbrooki subsp. A health food composition for preventing or improving liver fibrosis, comprising the lactis CKDB001 strain. 9. The method of claim 8,
The health food is at least one selected from the group consisting of drinks, meat, sausage, bread, candy, snacks, noodles, ice cream, dairy products, soups, ionic drinks, beverages, alcoholic beverages, gum, tea and vitamin complexes, A health food composition for preventing or improving liver fibrosis.

Images